2210-74-4 + 5294-61-1 = 95635-56-6 反应条件:1.1 Solvents: Methyl Ethyl Ketone; 4 H,70 - 85 °C; 85 °C -> 30 °C1.2 Reagents: Hydrochloric Acid,Compd. With 2-Propanol (1:1); 20 - 30 °C; 2 H,20 - 30 °C 标题:Process For Preparation Of Ranolazine And Salts Thereof 参考文献:India]
1131-01-7 + 162712-35-8 = 95635-56-6 反应条件:1.1 Reagents: Potassium Carbonate,Sodium Iodide Solvents: Dimethylformamide; 18 H,30 - 35 °C1.2 Reagents: Water1.3 Reagents: Hydrochloric Acid Solvents: Isopropanol,Acetone; Acidified 标题:Crystalline And Amorphous Form Of Ranolazine And The Process For Manufacturing Them 参考文献:World Intellectual Property Organization]
= 95635-56-6 [标题:Reaction Conditions 标题:Novel Solid State Forms Of Ranolazine Salts 参考文献:United States]
= 95635-56-6 [标题:Reaction Conditions 标题:A Process For The Preparation Of Ranolazine 参考文献:India]
= 95635-56-6 [标题:Reaction Conditions 标题:Novel Solid State Forms Of Ranolazine Salts For Treatment Of Cardiovascular Disorders 参考文献:World Intellectual Property Organization]
= 95635-56-6 [标题:Reaction Conditions 标题:Improved Process For The Preparation Of Ranolazine 作者:Anonymous 参考文献:Ip.Com Journal 日期:2009 卷标:9]
= 95635-56-6 [标题:Reaction Conditions 标题:Process For The Preparation Of Ranolazine Via Coupling Of N-(2,6-Dimethylphenyl)-1-Piperazineacetamide With 1-Methoxy-2-Oxiranylmethoxy)Benzene. 参考文献:World Intellectual Property Organization]
= 95635-56-6 [标题:Reaction Conditions 标题:Cardioselective Aryloxy- And Arylthiohydroxypropylpiperazinyl Acetanilides Which Affect Calcium Entry 参考文献:European Patent Organization
1: Pettus J, McNabb B, Eckel RH, Skyler JS, Dhalla A, Guan S, Jochelson P, Belardinelli L, Henry RH. Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. Diabetes Obes Metab. 2016 May;18(5):463-74. doi: 10.1111/dom.12629. Epub 2016 Feb 23. doi: 10.1177/1753944716636042. Epub 2016 Mar 3. Review. doi: 10.1016/j.ijcard.2016.02.140. [Epub ahead of print] Review. doi: 10.1002/clc.22476. Epub 2015 Oct 13. Review. doi: 10.5115/acb.2016.49.1.7. Epub 2016 Mar 28. 9: Rayner-Hartley E, Sedlak T. Ranolazine: A Contemporary Review. J Am Heart Assoc. 2016 Mar 15;5(3). pii: e003196. doi: 10.1161/JAHA.116.003196. Review. doi: 10.1016/j.ijcard.2015.10.180. Epub 2015 Oct 26. doi: 10.1161/CIRCULATIONAHA.115.019768. Epub 2015 Nov 10. doi: 10.1093/cvr/cvv247. Epub 2015 Nov 3. doi: 10.1371/journal.pone.0150619. eCollection 2016. 16: Mihos CG, Krishna RK, Kherada N, Larrauri-Reyes M, Tolentino A, Santana O. The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials. Pharmacol Res. 2016 Jan;103:49-55. doi: 10.1016/j.phrs.2015.10.018. Epub 2015 Nov 4. Review. doi: 10.1016/S0140-6736(15)00458-4. Epub 2015 Oct 22. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Jan 9;387(10014):136-45. doi: 10.1016/S0140-6736(15)00459-6. Epub 2015 Oct 22. doi: 10.1016/j.rec.2015.02.027. Epub 2015 Jul 14. doi: 10.1186/s12913-015-1228-y.
合成参考文献
参考文献:10.1371/journal.pone.0218897 摘要:Miller TW, Amason JD, Garcin ED, Lamy L, Dranchak PK, Macarthur R, Braisted J, Rubin JS, Burgess TL, Farrell CL, Roberts DD, Inglese J. Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. PLoS ONE. 2019 Jul 05;14(7):e0218897. doi: 10.1371/journal.pone.0218897.